ADB-CHMINACA

ADB-CHMINACA (also known as MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication. It was identified in cannabinoid blends in Japan in early 2015. Originally developed in 2009 by Pfizer with the intention to be tested for analgesic properties, MAB-CHMINACA soon proved to have other features that appeal to advanced researchers.

According to the results of initial observations, the substance displays a very high affinity for CB1 receptors at 0.289 nM, which is considerably above values measured for some of the conventional synthetic cannabinoids. New product is structurally related to several other indazole-based chemicals including AB-FUMINACA and AB-CHMINACA but is unique because of a tert-butyl group substituting the isobutyl moiety in the molecular chain. Due to its novelty, little is presently known about the physical and chemical properties of MAB-CHMINACA for sale online, and its pharmacological profile will have to be mapped by quantitative research. Buy MAB-CHMINACA online

Chemical Structure

Order ADB-CHMINACA online | Buy MAB-CHMINACA online

Omega Chem Solutions is a reliable source of MAB-CHMINACA of very high purity, with guaranteed delivery to specified addresses anywhere in the world. Please note that local restrictions or regulations could apply to this chemical and verify its current legal status before placing an order. The product may only be used for controlled scientific research under the strict supervision of qualified laboratory personnel and is not approved for pharmaceutical or veterinary purposes. Any kind of application outside of in vitro experiments represents a breach of our policies and could have potentially hazardous consequences.